| Karl Michael Trippe, MD | |
|
7100 Old Mcgregor Rd, Waco, TX 76712-6120 | |
| (254) 399-6545 | |
| (844) 244-3902 |
| Full Name | Karl Michael Trippe |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 7100 Old Mcgregor Rd, Waco, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285615674 | NPI | - | NPPES |
| 092311205 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | K3028 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reliable Home Health Services | Waco, TX | Home health agency |
| Providence Health Center | Waco, TX | Hospital |
| Baylor Scott & White Medical Center Hillcrest | Waco, TX | Hospital |
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Privia Medical Group Gulf Coast Pllc | 4688999022 | 397 |
News Archive
Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.
› Verified 6 days ago
| Entity Name | Ucp Physicians Of Central Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922289412 PECOS PAC ID: 3173697935 Enrollment ID: O20080729000203 |
News Archive
Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.
› Verified 6 days ago
| Entity Name | Waco Primary Care, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245528249 PECOS PAC ID: 4789856204 Enrollment ID: O20111005000698 |
News Archive
Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.
› Verified 6 days ago
| Entity Name | Privia Medical Group Gulf Coast Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578969465 PECOS PAC ID: 4688999022 Enrollment ID: O20150206000763 |
News Archive
Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karl Michael Trippe, MD 7100 Old Mcgregor Rd, Waco, TX 76712-6120 Ph: (254) 399-6545 | Karl Michael Trippe, MD 7100 Old Mcgregor Rd, Waco, TX 76712-6120 Ph: (254) 399-6545 |
News Archive
Just what causes the birth of a human fat cell is a mystery, but scientists using mathematics to tackle the question have come up with a few predictions about the proteins that influence this process.The research is intended to increase understanding of how and why preadipocytes, or pre-fat cells, either lie dormant, copy themselves or turn into fat. But the findings eventually could lead to a way to freeze these early cells in their current state before they can ever become the basis of fat tissue, according to Ohio State University researchers.
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
A new Northwestern University study reaffirms the importance of getting a good night's sleep.
Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.
› Verified 6 days ago
Allison L Hulme, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1600 Providence Dr, Waco, TX 76707 Phone: 254-750-8200 Fax: 254-750-8326 | |
Timothy Martindale, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7104 New Sanger Rd, Waco, TX 76712 Phone: 254-741-1113 Fax: 254-741-1342 | |
Dr. Brian Douglas Bull, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 851 North Loop 340, Waco, TX 76705 Phone: 254-202-7500 Fax: 254-202-7599 | |
Dr. Matthew R Porter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 W. State Hwy 6, Waco, TX 76712 Phone: 254-313-6700 Fax: 254-313-4531 | |
Lianda Mirella Martinez, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Franklin Ave, Suite B-c, Waco, TX 76701 Phone: 254-537-6590 Fax: 254-537-6599 | |
Dr. Aman A Shah, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Hillcrest Medical Blvd, Waco, TX 76712 Phone: 254-202-2000 | |
Dr. Rita L Haws, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1600 Providence Dr, Waco, TX 76707 Phone: 254-313-4200 Fax: 254-313-4549 |